Resistance to apoptosis is well documented as one of the hallmarks of cancer, 1 and the Bcl-2 family of proteins play a critical role in regulating the intrinsic apoptosis process in response to apoptotic stimuli. The structurally related Bcl-2 protein family is structurally and functionally classified as either anti-apoptotic (e.g. Bcl-2, Bcl-x L , Bcl-w, Mcl-1); pro-apoptotic (e.g. Bak, Bax, Bcl-rambo); or as pro-apoptotic BH3 domain only proteins (e.g. Bad, BID, Bim, Noxa) that bind and regulate anti-apoptotic Bcl-2 proteins. The carefully regulated balance between pro-and anti-apoptotic protein family members is crucial in dictating cellular survival or commitment to apoptosis. 2 In terms of development of new cancer therapeutics, small molecule anti-apoptotic Bcl-2 inhibitors offer exciting prospects. 3 Following Bcl-2 inhibition, the resulting cellular mitochondrial membrane permeabilisation and release of pro-apoptotic factors commits the cell to apoptosis and subsequent removal. Resistance to apoptotic stimuli is commonly induced by overexpression of anti-apoptotic Bcl-2 proteins that are also known to contribute to therapy failure and subsequent generation of a more resistant cancer phenotype. 2 The exciting potential of small molecule anti-apoptotic Bcl-2 inhibitors in cancer therapy has led to a number of advances in this area, 3, 4 focusing on the design of new cell permeable small molecule inhibitors that block sites of protein-protein interaction 5 between anti-apoptotic Bcl-2 family proteins and pro-apoptotic partners. Amongst the most advanced and well-documented examples of Bcl-2 inhibitors that have progressed to clinical evaluation are the orally bioavailable navitoclax (ABT-263, 1), obatoclax (2) and the polyphenolic natural product-based experimental drug gossypol (3), shown in Figure 1 . Perhaps most significantly, the Bcl-2 inhibitor venetoclax (ABT-199, 4) has been granted breakthrough designation by the FDA for treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have the 17p chromosomal deletion. 6 One notable feature of the first generation of anti-apoptotic Bcl-2 family inhibitors is their large size (M r = 975 in the case of navitoclax) and chemical complexity, in part arising from the perceived requirement to make multiple drug binding interactions across a substantial protein-protein interaction interface. The development of smaller, less complex molecules that retain selective Bcl-2/Bcl-XL inhibition and antitumour activity is an ongoing challenge. The pro-apoptotic Bcl-2 inhibitory compound obatoclax mesylate 7 suggests that structurally simple heterocylic compounds may possess the necessary characteristics for selective Bcl-2 inhibitory antitumour properties. Previous work within our group has identified pro-apoptotic Bcl-2 inhibitory compounds of the indolyl-oxadiazole, 8 isoxazole 9 and indolyltriazole 10 classes; in this paper we report the discovery and early A series of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines 8a-j has been designed, synthesized and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents based on our previous lead compound 8a. Synthesis of the target compounds was readily accomplished through a cyclisation reaction between indole-3-carboxylic acid hydrazide (5) and substituted isothiocyanates 6a-j, followed by oxidative cyclodesulfurization of the corresponding thiosemicarbazide 7a-j using 1,3-dibromo-5,5-dimethylhydantoin. Active compounds of the series 8a-j were found to have sub-micromolar IC50 values selectively in Bcl-2 expressing human cancer cell lines; notably the 2-nitrophenyl analogue 8a was found to exhibit potent activity, and compounds 8a and 8e possessed comparable Bcl-2 binding affinity (ELISA assay) to the established natural product-based Bcl-2 inhibitor, gossypol. Molecular modeling studies helped to further rationalise anti-apoptotic Bcl-2 binding, and identified compounds 8a and 8e as candidates for further development as Bcl-2 inhibitory anticancer agents.
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Anti-apoptotic Bcl-2 Indoles Oxadiazoles Anticancer Drug discovery evaluation of a new series of Bcl-2 inhibitory 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines. The lead compound for this study (8a) was obtained as a virtual screening hit of the ZINC database against a Bcl-2 pharmacophore model, using methodology previously described. 11 Structure activity relationships were studied by variation of the phenyl/benzyl group substituents that bind within a hydrophobic groove of our model, as shown in Scheme 1. Synthesis of the target compounds was readily achieved in two synthetic steps, through adaptation of a literature route. 12, 13 The first step involved heating indole-3-carbonylhydrazide (5) with substituted phenyl/benzyl isothiocyanates (6a-j) in refluxing ethanol to produce the intermediate thiosemicarbazide (7a-j) that was used in the next step without further purification. 14 
Treatment
of the indolyl-3-carbonyl-N-phenyl/benzyl thiosemicarbazide (7a-j) with KI and 1,3-dibromo-5,5dimethylhydantoin in basic solution afforded the product 5-(1Hindol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines (8a-j) in high yield (58-86%) following recrystallisation from ethanol. 15, 16 Evaluation of the newly synthesized indolyl-oxadiazolamines was carried out across four human cancer cell lines. Viability in the established triple-negative breast cancer cell line MDA-MB-231 and cervical cancer (HeLa) cells (both Bcl-2 expressing) was assessed using the MTT endpoint assay. To test the effect of differing Bcl-2 status, further evaluation of new compounds was carried out in the human cancer cell lines KG1a (acute myelogenous leukaemia) and Jurkat (T cell leukaemia). The Jurkat cell line has previously been characterized as Bcl-2 negative by our group 17 and others, 18 unlike the Bcl-2 expressing KG1a cell line. 19 For studies on the leukaemic cells we used the CellTiter-Blue® viability assay, appropriate for endpoint determinations in these non-adherent cells. The results, expressed as mean values following testing on at least three separate occasions, are presented in Table 1 .
The results shown in Table 1 indicated that in general the HeLa cell line was the most sensitive to the effects of test compounds with IC 50 values in the sub-to low-micromolar range of 0.3 -19 µM (with the exception of inactive compound 8g). The MDA-MB-231 breast cancer cell line also gave sub-to lowmicromolar IC 50 values for the majority of new compounds. The observation of sub-to low-micromolar inhibitory activity for the majority of compounds in the Bcl-2 expressing KG1a leukaemic cell line, but not in the Bcl-2 negative T-cell leukaemia Jurkat cells, suggests that Bcl-2 may play a role in mediating the observed anticancer activity.
The most active compound overall was the 2-nitrophenyl derivative 8a that shows potent (sub-micromolar) IC 50 values across the three Bcl2-expressing human cancer cell lines (MDA-MB-231, HeLa and KG1a) with less potent inhibitory activity in the Bcl-2 negative Jurkat cells. The most active and selective compounds from the cell line assay (8a, 8c and 8e) , along with moderately active compounds 8h and 8i were chosen for more detailed mechanistic study using the enzyme-linked immunosorbent (ELISA) sandwich binding assay along with gossypol as positive control.
The ELISA assay was used to determine the ability of the test compounds to compete with immobilized Bim peptide for binding to His-tagged Bcl-2 protein, according to our previously described protocol 10, 19 (see Supplementary Information) . The ELISA binding results ( Table 2 ) displayed some consistency with the predicted activity of the killing pattern, in that the potently active compound 8e showed similar binding affinity to Bcl-2 compared with reference standard gossypol. Compound 8e was found to be two-fold more active than our initial lead compound 8a. Further evidence that Bcl-2 might be responsible for the observed anticancer activity of the new indolyl-N-aryloxadiazolamines was obtained through molecular modeling studies. Interactions between the most active compounds 8a and 8e, and a published Bcl-2 crystal structure (PDB code 4AQ3 20 ), were studied within MOE 21 making use of the LeadIt software 22 for analyzing molecular interactions. Docking of compound 8a at the Bim peptide-binding site revealed that 8a mimics residues Leu95 and Ile97 of Bim, making important interactions between Leu96 and the extracellular NH group, and between Arg105 and the oxadiazole ring nitrogen (3-position), within the Bcl-2 hydrophobic groove. Compound 8e occupies a similar Bcl-2 binding site mimicking the Phe101, Leu95, and Ile97 residues of Bim peptide, similarly making interactions between Leu96 and the extracellular NH group, and between Arg105 and the oxadiazole ring nitrogen (3-position) . For compound 8e, an additional interaction between key Bcl-2 hydrophobic groove residue Tyr67 and the indole ring of 8a is apparent. Representations of the binding models of 8a (A) and 8e (B) within the Bcl-2 hydrophobic pocket are shown in Figure 2 . 
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